Compugen Ltd. announced appointment of Dr. Henry Adewoye, to the newly created position of Chief Medical Officer, effective immediately. As Chief Medical Officer, he will play a key role in leading the company's transition into a clinical stage company, and will assume overall responsibility of company's clinical stage pipeline programs. He will be based at company's South San Francisco facilities. He joins the company from Gilead Sciences Inc., where he most recently served as clinical director in oncology clinical research, was on the oncology leadership team and held positions of increasing responsibility as project team and clinical lead for multiple phase 1-3 programs, Andecaliximab, GS-9901, and Acalisib. Prior to Gilead, he was clinical research medical director in oncology at Amgen Inc. and global medical monitor for the initial registrational trial of the bispecific antibody blinatumomab and several phase 2 and 3 studies evaluating VEGF inhibitors in patients with solid tumors.